Vitamin C: Evidence Review | Evidentia Nutrition

What it is

Vitamin C (ascorbic acid) is a water-soluble vitamin that humans cannot synthesise and must obtain from diet. It is found in high concentrations in citrus fruits, berries, kiwi, peppers, broccoli, and many other plant foods. Unlike most mammals, humans and other primates lack a functional gene for the final enzymatic step of ascorbic acid biosynthesis, making dietary intake essential.

Ascorbic acid functions as a reducing agent and cofactor for a range of enzymatic reactions. Its roles include collagen synthesis (via hydroxylation of proline and lysine residues in procollagen), carnitine biosynthesis, catecholamine production, and the regeneration of other antioxidants including vitamin E. It is also a direct antioxidant capable of scavenging reactive oxygen species in aqueous environments.

Supplemental forms include ascorbic acid (the most studied and least expensive form), mineral ascorbates including sodium ascorbate and calcium ascorbate (buffered forms with equivalent bioavailability at matched doses), and liposomal vitamin C (which achieves higher acute plasma concentrations than standard oral forms, though the clinical relevance of this is not established).

What the evidence shows

The vitamin C evidence base is a case study in the importance of population context. The evidence is strong for well-defined outcomes in low-status individuals and specific at-risk groups, and consistently null for the broader prevention claims that drive most commercial interest. An important interpretive boundary runs through this evidence: vitamin C modulates immune biomarkers in low-status individuals, but these changes do not translate into meaningful reduction in infection incidence in replete adults.

Deficiency correction and repletion represent the clearest application. In individuals with low or deficient vitamin C status, supplementation reliably corrects biochemical markers and resolves or prevents deficiency symptoms. This is a nutritional correction effect, not a pharmacological one, and the evidence is consistent and uncontested.

Common cold, general population. The most widely cited Cochrane review (Hemila and Chalker) pooled over 10,000 participants across more than 30 trials. Regular supplementation (not therapeutic dosing at onset) modestly reduces cold duration, approximately 8% relative reduction in adults (typically less than one day in absolute terms) and 14% in children. It does not reduce cold incidence in the general population. Starting supplementation after cold onset does not meaningfully affect duration or severity. This is a useful signal but a modest one, and it does not support the widespread perception that high-dose vitamin C prevents or cures colds in ordinary healthy adults.

Common cold, high-stress populations. A distinct and robust subgroup finding from the same evidence base shows approximately 50% reduction in cold incidence in people exposed to brief periods of extreme physical stress, marathon runners, skiers, soldiers on intensive exercise. This effect is specific to this context and does not generalise.

Iron absorption. Vitamin C reliably enhances non-haem iron absorption when consumed simultaneously with iron-containing food or supplements. The mechanism is well-understood: ascorbic acid reduces ferric iron to ferrous iron, which is more readily absorbed, and forms soluble chelate complexes that prevent precipitation. This interaction is clinically useful for individuals with low iron status or those relying on plant-based iron.

Cardiovascular and cancer prevention in replete adults. Large, well-powered trials including the Physicians' Health Study II, the Women's Antioxidant Cardiovascular Study, and the SU.VI.MAX trial are consistently null for hard endpoints including cardiovascular events and cancer incidence. The observational associations frequently cited in support of vitamin C's protective role do not survive intervention testing.

Skin and collagen. Vitamin C is essential for collagen synthesis and low status is associated with impaired wound healing. For individuals with adequate status, supplementation's effect on skin outcomes such as wrinkle reduction or photoageing attenuation is an emerging area with some small positive trials, but the evidence is not sufficiently consistent or robust to support confident conclusions. Many reviews conflate topical and oral evidence, which should not be treated as equivalent.

The five questions

Does low status cause harm that supplementation corrects?

Yes, clearly. Vitamin C deficiency causes scurvy, a serious and potentially fatal condition characterised by impaired collagen synthesis, bleeding gums, poor wound healing, and systemic fragility. Deficiency is rare in high-income populations but not absent, particularly in older adults, smokers, those with limited dietary variety, and individuals with malabsorption. Low status short of frank deficiency is associated with reduced antioxidant capacity and impaired immune biomarkers. Repletion corrects these effects reliably, though improvements in immune biomarkers in low-status individuals should not be interpreted as evidence of infection prevention in the general population.

Does supplementation prevent disease in at-risk populations?

Yes, in a specific and limited sense. Regular supplementation prevents scurvy in individuals unable to meet requirements through diet. For cold prevention specifically, a meaningful protective effect exists in individuals under acute physical or environmental stress. Beyond these contexts the prevention evidence is not compelling.

Does vitamin C produce meaningful biomarker effects?

Yes for iron absorption, reliably and via a well-characterised mechanism. For antioxidant biomarkers (plasma ascorbate, oxidative stress markers) supplementation produces expected biochemical effects in low-status individuals, but these do not translate to hard clinical benefit in replete populations as established by large trials.

Does vitamin C improve outcomes in clinical populations?

Evidence for benefit in clinical populations beyond deficiency correction is limited and context-specific. There is reasonable evidence for benefit in acute critical illness (though the optimal dose, timing, and route are still being investigated), and in the specific cold prevention context noted above. For most chronic disease applications the trial evidence is null or insufficient.

Does vitamin C benefit healthy, replete adults?

Beyond modest cold duration reduction, the evidence for supplementation in replete healthy adults is not compelling for most outcomes. The large prevention trials are consistently null. Routine supplementation is low-risk but the rationale for supplementing in individuals with good dietary intake is not strongly evidence-based.

Individual variation

Smokers have meaningfully higher vitamin C requirements due to increased oxidative turnover from tobacco smoke. UK dietary reference values reflect this with a higher recommended intake for smokers. Low-status individuals, whether from inadequate diet, malabsorption, or high physiological demand, benefit more clearly from supplementation than replete individuals.

Individuals relying on plant-based iron sources represent a practical use case where vitamin C co-consumption is well-supported. Those with predisposition to calcium oxalate kidney stones should be aware that high-dose supplementation increases urinary oxalate excretion.

There is no well-established genetic variation that materially affects vitamin C requirements in the general population, though SVCT2 transporter variants affecting tissue distribution have been studied in research contexts.

Testing and status assessment

Plasma ascorbate concentration is the standard measure of vitamin C status. Values below 11 micromol/L indicate deficiency; values below 28 micromol/L indicate low status. Leukocyte ascorbate provides a better measure of tissue stores but is less commonly used in routine clinical practice.

Status testing is most useful in individuals at elevated risk of low status: smokers, older adults with limited dietary variety, those with malabsorption conditions, individuals recovering from surgery or serious illness. For most adults eating a varied diet including fruits and vegetables, testing is unlikely to change clinical management.

Safety

Vitamin C is well-tolerated across a wide dose range. GI side effects, diarrhoea, nausea, abdominal discomfort, are the primary dose-limiting factor and typically occur above 1,000mg per day in most individuals. The tolerable upper intake level of 2,000mg per day reflects this. High-dose supplementation is not appropriate for individuals with haemochromatosis or other iron overload conditions given the enhancement of iron absorption. Individuals with a history of kidney stones, particularly calcium oxalate stones, should avoid high-dose supplementation. Laboratory test interference at high doses is a practical consideration for clinical settings.

What can reasonably be concluded

Vitamin C has a well-established and important role in correcting low status, in collagen synthesis, and in enhancing iron absorption. The evidence for cold duration reduction in the general population is real but modest, less than one day in absolute terms, and the popular belief in high-dose vitamin C as a cold cure is not well-supported by the trial evidence. The meaningful cold prevention effect is specific to individuals under acute physical or environmental stress.

For replete healthy adults, the large prevention trials provide consistent null findings for cardiovascular disease and cancer. Supplementation in this context is unlikely to cause harm at conventional doses but the evidence base does not support a strong clinical rationale.

The strongest case for vitamin C supplementation is in individuals at risk of low status, smokers, older adults with limited dietary variety, those with malabsorption, and in the specific context of iron absorption optimisation. The core evidence base for vitamin C is mature, with most large trials completed before 2010; this reflects the settled nature of the primary findings rather than a gap in the literature. Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.